RYBELSUS 7MG TABLETS
Item requires a valid prescription
Manufactured By NOVO NORDISK PHARMA INDIA LTD
Composition SEMAGLUTIDE 7MG
RS 2970.00
MRP RS 3300.00
(10% OFF)
Includes all taxes
Package SIZE
( 10`s )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Rybelsus 7mg Tablet
Rybelsus 7mg Tablet (Semaglutide 7mg) is a first-in-class oral GLP-1 receptor agonist manufactured by Novo Nordisk Pharma India Ltd, indicated for improving glycaemic control in adults with Type 2 Diabetes Mellitus (T2DM) as an adjunct to diet and exercise. Rybelsus is the world's first oral semaglutide tablet — previously, semaglutide was only available as a subcutaneous injection (Ozempic). Made possible by the SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption-enhancer technology, Rybelsus delivers clinically meaningful GLP-1 activity through a convenient once-daily oral dose. Available from Shabbir Medical Hall at 10% OFF MRP, this genuine Novo Nordisk prescription tablet is available online with fast delivery nationwide.
BENEFITS: Rybelsus 7mg works as a GLP-1 (glucagon-like peptide-1) receptor agonist, mimicking the body's natural incretin hormone. It stimulates glucose-dependent insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite — resulting in significant HbA1c reductions (up to 1.4% in clinical trials) and meaningful body weight reduction. Rybelsus 7mg is the dose used after the 3mg starter dose for the first month to assess tolerability, before consideration of escalation to 14mg for additional glycaemic control. Unlike insulin, Rybelsus carries a low risk of hypoglycaemia when used as monotherapy.
USAGE OVERVIEW: Rybelsus 7mg must be taken FASTING — on an empty stomach with no more than 120 mL (half a glass) of plain water, at least 30 minutes before the first food, drink, or other oral medication of the day. Taking it with food or other liquids drastically reduces absorption. Do NOT crush, split, chew, or dissolve the tablet — swallow whole.
SAFETY OVERVIEW: Most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — typically transient and most pronounced at treatment initiation. Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Not for use in Type 1 diabetes. Prescription required.
Uses / Indications:
• Type 2 Diabetes Mellitus (T2DM): to improve glycaemic control in adults, as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents (metformin, SGLT-2 inhibitors, sulfonylureas, basal insulin)
RYBELSUS DOSE TITRATION:
• 3mg once daily for the first 30 days (starter/tolerability dose — NOT therapeutic)
• 7mg once daily from Day 31 (maintenance therapeutic dose)
• 14mg once daily if additional glycaemic control is needed after ≥30 days on 7mg
ADDITIONAL BENEFITS (supported by clinical evidence):
• Weight reduction: average 2–4 kg body weight loss in PIONEER clinical trials
• Cardiovascular benefit: PIONEER 6 trial demonstrated non-inferior CV safety vs placebo
• Used off-label or under investigation for: NASH/MASLD, obesity management in T2DM
Interactions / Warnings:
THYROID TUMOUR WARNING (BLACK BOX — US label): Semaglutide caused dose-dependent thyroid C-cell tumours in rodent studies. CONTRAINDICATED in personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Report any neck lump, persistent hoarse voice, or difficulty swallowing immediately.
PANCREATITIS PRECAUTIONS: Discontinue if acute pancreatitis is confirmed — do not restart. Use with caution in patients with history of pancreatitis.
DIABETIC RETINOPATHY: Rapid HbA1c reduction at initiation may temporarily worsen retinopathy in patients with pre-existing retinopathy — ophthalmology review recommended before starting.
RENAL IMPAIRMENT: No dose adjustment required for renal impairment, but monitor closely in severe renal impairment due to dehydration risk from GI side effects.
HEPATIC IMPAIRMENT: No dose adjustment required for mild/moderate; use with caution in severe hepatic impairment — limited data available.
HYPOGLYCAEMIA: Low risk as monotherapy or with metformin (glucose-dependent mechanism). Significant risk when combined with insulin or sulfonylureas — consider dose reduction of the latter.
FOOD INTERACTION: MUST be taken on an empty stomach with ≤120mL plain water — 30 minutes before any food or other oral medicine.
DRIVING & MACHINERY: Low risk of hypoglycaemia as monotherapy; caution if combined with insulin/SU.
TYPE 1 DIABETES: NOT indicated for Type 1 Diabetes or diabetic ketoacidosis.
Pregnancy interaction:
• Rybelsus (Semaglutide) is CONTRAINDICATED in pregnancy — semaglutide caused fetal abnormalities in animal studies
• Discontinue Rybelsus at least 2 months before a planned pregnancy
• Women of childbearing age must use effective contraception while on Rybelsus
• If pregnancy is detected during treatment, discontinue immediately
BREASTFEEDING:
• NOT recommended during breastfeeding — semaglutide may be excreted in breast milk
• Discuss alternative antidiabetic therapy with your physician
FERTILITY:
• No human data on effects on fertility; animal studies showed no direct impairment
• Weight loss from Rybelsus may improve fertility in obese women with T2DM indirectly
Expert advice:
1. STRICT EMPTY STOMACH RULE — THE MOST IMPORTANT INSTRUCTION:
• Rybelsus MUST be taken first thing in the morning on a completely empty stomach with NO MORE THAN 120mL of plain water only. No coffee. No tea. No juice. No other liquids. No food. No other medicines. Then wait a FULL 30 MINUTES before your first meal or any other oral medication. Missing this rule can reduce semaglutide absorption by up to 90%, making the tablet ineffective. This is the single most common reason patients fail to see results with Rybelsus — always verify this with your patients.
2. MANAGE NAUSEA AT INITIATION — START LOW, GO SLOW:
• The 3mg starter dose exists precisely to allow GI tolerance to build. Most nausea is temporary and improves within 2–4 weeks. Advise patients to eat smaller meals, avoid fatty/spicy food, stay well-hydrated, and not discontinue prematurely due to nausea. Domperidone or ondansetron may help in consultation with the physician.
3. PANCREATITIS VIGILANCE:
• Any severe, persistent mid-upper abdominal pain radiating to the back is a RED FLAG for acute pancreatitis. Patients must stop Rybelsus immediately and seek emergency care. Do not restart semaglutide after confirmed pancreatitis.
4. THYROID SURVEILLANCE:
• Counsel patients to report any new lump in the neck, voice changes, or difficulty swallowing. While human thyroid risk is not confirmed, the precaution stands — especially in patients with thyroid nodules or family history of thyroid cancer.
5. DIABETIC RETINOPATHY — SCREEN BEFORE STARTING:
• Rapid HbA1c reduction (especially from very high baseline) can temporarily worsen diabetic retinopathy. Ophthalmology review is advisable before initiating Rybelsus in patients with known retinopathy.
MONITORING ADVICE:
• HbA1c: At baseline, then every 3 months until stable, then every 6 months
• Fasting Blood Glucose / Post-Prandial Glucose: Monthly initially
• Body Weight: Monthly — expect gradual reduction
• Renal Function (Serum Creatinine / eGFR): Every 6–12 months
• Liver Function Tests: At baseline and annually
• Lipid Panel: Annually (semaglutide may improve lipid profile)
• Thyroid palpation / USS: If symptoms arise
• Retinal Assessment: Baseline and annually in T2DM
COMPLIANCE TIPS:
• Set a phone alarm for first thing in the morning — before bed/bathroom routine, place the tablet strip and a measured 120mL glass of water on your bedside table
• Keep a dose diary with time taken and any GI symptoms noted
• Do NOT crush, split, chew, or dissolve tablets — swallow whole
• Maintain all planned follow-up blood tests and physician reviews
SAFETY TIPS:
• Rybelsus is not for Type 1 Diabetes or DKA
• Carry a fast-acting glucose source if also on insulin or sulfonylurea
• Inform all treating doctors and surgeons you are on semaglutide (may affect anaesthesia due to gastric emptying delay)
• Discontinue ≥2 months before planned pregnancy
Side Effects:
• Nausea (most common — especially at initiation and dose escalation)
• Diarrhoea
• Vomiting
• Decreased appetite
COMMON SIDE EFFECTS (1 in 10 to 1 in 100):
• Constipation
• Abdominal discomfort, bloating, flatulence
• Dyspepsia / indigestion
• Fatigue
• Hypoglycaemia (when combined with insulin or sulfonylurea)
• Weight loss
• Increased heart rate (mild)
SERIOUS SIDE EFFECTS (contact your doctor immediately):
• Acute Pancreatitis: severe persistent upper abdominal pain radiating to back — STOP medication and seek immediate care
• Thyroid Tumours (rare): lump/swelling in neck, hoarse voice, difficulty swallowing or breathing — seek urgent evaluation
• Diabetic Retinopathy Complications: visual changes — especially with rapid HbA1c reduction at initiation
• Severe Hypoglycaemia: (when used with insulin/sulfonylurea) — dizziness, confusion, sweating, tremors — treat with fast-acting glucose
• Acute Kidney Injury: nausea/vomiting may reduce fluid intake → dehydration → renal impairment — monitor renal function
EMERGENCY SIGNS — SEEK IMMEDIATE MEDICAL HELP:
• Severe/persistent abdominal pain (pancreatitis)
• Neck lump, voice changes (thyroid)
• Sudden vision changes (retinopathy)
• Signs of severe dehydration/renal failure
How to use:
• Starter Dose: Rybelsus 3mg once daily for first 30 days
• Maintenance Dose: Rybelsus 7mg once daily from Day 31 onward
• Escalation: If additional glycaemic control needed after ≥30 days on 7mg → Rybelsus 14mg
CRITICAL ADMINISTRATION RULE — EMPTY STOMACH PROTOCOL:
• Take FIRST THING IN THE MORNING on an EMPTY STOMACH
• Use ONLY plain water — no more than 120 mL (half a standard glass)
• Wait AT LEAST 30 MINUTES before eating, drinking anything else, or taking other oral medicines
• Do NOT take with coffee, tea, juice, milk, or flavoured water — this significantly reduces absorption
• Do NOT crush, split, chew, or dissolve the tablet — swallow WHOLE
ROUTE:
• Oral tablet — one tablet once daily
MISSED DOSE:
• If you missed your morning dose and it is BEFORE the 30-minute window: take it if you haven't eaten yet and can still wait 30 minutes
• If you have already eaten: SKIP the dose that day — do not take it later
• Never double up doses
DURATION:
• Long-term ongoing therapy as directed by physician
• Do not discontinue without medical advice — blood sugar may rise
STORAGE:
• Store below 30°C away from direct sunlight and moisture
• Keep in original blister/strip
• Keep out of reach of children
• Do not use after expiry date on label
How it works:
GLP-1 (glucagon-like peptide-1) is a natural incretin hormone secreted by intestinal L-cells in response to food intake. In Type 2 Diabetes, GLP-1 secretion and receptor sensitivity are impaired.
Semaglutide works by:
1. INSULIN STIMULATION:
• Activates GLP-1 receptors on pancreatic beta-cells → stimulates insulin secretion in a GLUCOSE-DEPENDENT manner (only when blood glucose is elevated — minimal hypoglycaemia risk)
2. GLUCAGON SUPPRESSION:
• Inhibits glucagon release from pancreatic alpha-cells → reduces hepatic glucose output and post-meal blood sugar spikes
3. GASTRIC EMPTYING DELAY:
• Slows the rate at which food leaves the stomach → blunts post-meal glucose rise and promotes earlier satiety
4. APPETITE REDUCTION:
• Acts on hypothalamic appetite centres → reduces caloric intake and supports weight loss
ORAL DELIVERY (SNAC Technology):
• Semaglutide is a large peptide normally degraded in the GI tract
• Rybelsus co-formulates semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that raises local pH in the stomach to protect semaglutide from pepsin degradation and promotes transcellular absorption across gastric mucosa
• This is why Rybelsus MUST be taken fasting with ≤120mL plain water only
CLINICAL RESULTS (PIONEER Trials):
• Rybelsus 7mg: HbA1c reduction ~1.2–1.4% vs placebo
• Body weight reduction: ~2–3 kg vs placebo
• Non-inferior to liraglutide (injectable GLP-1) in glycaemic control
• Statistically significant reduction in CV events vs placebo (PIONEER 6)
Faq for medicine:
Rybelsus 7mg (Semaglutide) is an oral GLP-1 receptor agonist used to improve blood sugar control in adults with Type 2 Diabetes Mellitus, taken once daily on an empty stomach as part of a diabetes management plan.
2. How does Rybelsus 7mg Semaglutide Tablet work?
Semaglutide mimics the GLP-1 hormone to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite — collectively lowering blood sugar and supporting body weight reduction.
3. What is the correct way to take Rybelsus 7mg Tablet?
Take Rybelsus 7mg FIRST THING IN THE MORNING on an empty stomach with ≤120mL plain water only. Wait 30 minutes before eating or taking other medicines. Swallow whole — never crush or chew. Follow physician's instructions.
4. What are the side effects of Rybelsus 7mg Tablet?
Most common: nausea, diarrhoea, vomiting, and decreased appetite — usually temporary and most pronounced at initiation. Serious but rare: acute pancreatitis, thyroid tumours, and diabetic retinopathy worsening.
5. Can I buy Rybelsus 7mg Tablet online at the best price in India?
Yes. Buy Rybelsus 7mg online from Shabbir Medical Hall at 10% OFF MRP (Rs 2,970 vs Rs 3,300 per strip of 10 tablets). Valid prescription required. Fast delivery across Hyderabad, Bangalore, Mumbai, Delhi, and Chennai.
Medicine interaction:
• Oral Medications requiring precise absorption (levothyroxine, warfarin, oral contraceptives): Rybelsus' gastric emptying delay may affect absorption timing — take these medications ≥30 minutes after Rybelsus or as directed by physician
• Insulin / Sulfonylureas: increased hypoglycaemia risk — dose reduction of insulin or sulfonylurea may be needed when combining with Rybelsus
• Metformin / SGLT-2 inhibitors (dapagliflozin, empagliflozin): commonly combined with semaglutide — generally safe; additive glycaemic and weight benefit
• DPP-4 inhibitors (sitagliptin, vildagliptin): avoid combination — both act on GLP-1 pathway; not recommended together
• Warfarin / anticoagulants: monitor INR more closely at initiation — semaglutide may affect warfarin levels indirectly
• Cyclosporine: increased cyclosporine exposure possible — monitor levels
FOOD INTERACTIONS:
• CRITICAL: Food, coffee, tea, juice, or any liquid other than ≤120mL plain water before taking Rybelsus will significantly reduce its absorption — always fast
SUPPLEMENT INTERACTIONS:
• No specific major supplement interactions known; inform doctor of all supplements
